[1]丁春梅,胡志德,刘晓斐,等.MR-proANP：一种新型心力衰竭诊断标志物[J].现代检验医学杂志,2015,30(05):99-101.[doi:10.3969/j.issn.1671-7414.2015.05.0030]
　DING Chun-mei,HU Zhi-de,LIU Xiao-fei,et al.MR-proANP：A Novel Diagnostic Marker for Heart Failure[J].Journal of Modern Laboratory Medicine,2015,30(05):99-101.[doi:10.3969/j.issn.1671-7414.2015.05.0030]
点击复制

MR-proANP：一种新型心力衰竭诊断标志物()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年05期
页码:
99-101
栏目:
综述
出版日期:
2015-12-10

文章信息/Info

Title:
MR-proANP：A Novel Diagnostic Marker for Heart Failure
作者:
丁春梅; 胡志德; 刘晓斐; 胡成进
济南军区总医院实验诊断科，济南250031
Author(s):
DING Chun-mei; HU Zhi-de; LIU Xiao-fei; HU Cheng-jin
Department of Laboratory Medicine， General Hospital of Ji’nan Military Region，Ji’nan 250031，China
关键词:
MR-proANP; 心力衰竭; 诊断; 呼吸困难
分类号:
R541.6；R446
DOI:
10.3969/j.issn.1671-7414.2015.05.0030
文献标志码:
A
摘要:
BNP和NT-proBNP是目前应用最为广泛的心力衰竭诊断标记物，但二者并非完美无缺。MR-proANP是近年来新发现的一种心力衰竭诊断标志物。已有的研究初步揭示了其在心力衰竭的诊断方面具有和BNP和NT-proBNP相媲美的临床价值，且其在一定程度上可以和BNP和NT-proBNP互补。该文就MR-proANP的由来及其在心力衰竭诊断中的价值作一综述。
Abstract:
BNP and NT-proBNP were the most widely used diagnostic marker for heart failure，however，they were not perfect．Recently，MR-proANP was reported to be a novel heart failure diagnostic marker．Available studies had found that MR-proANP had comparable diagnostic accuracy with BNP and NT-proBNP for heart failure，and its diagnostic ultility could compensate with BNP or NT-proBNP．The origin of MR-proANP and its diagnostic value for heart failure were reviewed in present study．

参考文献/References:

［1］Kim HN，Januzzi JL．Natriuretic peptide testing in heart failure［J］．Circulation，2011，123(18)：2015-2019．
[2]Mukoyama M，Nakao K，Hosoda K，et al．Brain natriuretic peptide as a novel cardiac hormone in humans．Evidence for an exquisite dual natriuretic peptide system，atrial natriuretic peptide and brain natriuretic peptide［J］．J Clin Invest，1991，87(4)：1402-1412．
[3]Ghosh N，Haddad H．Atrial natriuretic peptides in heart failure：pathophysiological significance，diagnostic and prognostic value［J］．Can J Physiol Pharmacol，2011，89(9)：587-591．
[4]Tzikas S，Keller T，Wild PS，et al．Midregional pro-atrial natriuretic peptide in the general population//Insights from the Gutenberg Health study［J］．Clin Chem Lab Med，2013，51(5)：1125-1133．
[5]Gruson D，Rousseau MF，Ahn S，et al．Accuracy of N-terminal-pro-atrial natriuretic peptide in patients admitted to emergency department［J］．Scand J Clin Lab Invest，2008，68(5)：410-414．
[6]Morgenthaler NG，Struck J，Thomas B，et al．Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma［J］．Clin Chem，2004，50(1)：234-236．
[7]Goode KM，Nicholls R，Pellicori P，et al．The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature［J］．Clin Chem Lab Med，2014，52(6)：911-918．
[8]Gegenhuber A，Struck J，Poelz W，et al．Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients：comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP［J］．Clin Chem，2006，52(5)：827-831．
[9]Chenevier-Gobeaux C，Guerin S，Andre S，et al．Mid-regional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department：A comparison with B-type natriuretic peptide(BNP) and N-terminal pro-BNP［J］．Clin Chem，2010，56(11)：1708-1717．
[10]Maisel A，Mueller C，Nowak R，et al．Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea：results from the BACH(biomarkers in acute heart failure) trial［J］．J Am Coll Cardiol，2010，55(19)：2062-2076．
[11]Potocki M，Breidthardt T，Reichlin T，et al．Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure［J］．J Intern Med，2010，267(1)：119-129．
[12]Richards M，Di Somma S，Mueller C，et al．Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients：results from the BACH study(Biomarkers in ACute Heart Failure)［J］．JACC Heart Fail，2013，1(3)：192-199．
[13]Meune C，Vermillet A，Wahbi K，et al．Mid-regional pro-atrial natriuretic peptide allows the accurate identification of patients with atrial fibrillation of short time of onset：a pilot study［J］．Clin Biochem，2011，44(16)：1315-1319．
[14]Daniels LB，Clopton P，Potocki M，et al．Influence of age，race，sex，and body mass index on interpretation of midregional pro-atrial natriuretic peptide for the diagnosis of acute heart failure：results from the BACH multinational study［J］．Eur J Heart Fail，2012，14(1)：22-31．
[15]Shah RV，Truong QA，Gaggin HK，et al．Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea［J］．Eur Heart J，2012，33(17)：2197-2205．
[16]Hu Z，Han Z，Huang Y，et al．Diagnostic power of the mid-regional pro-atrial natriuretic peptide for heart failure patients with dyspnea：a meta-analysis［J］．Clin Biochem，2012，45(18)：1634-1639．
[17]Seronde MF，Gayat E，Logeart D，et al．Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure［J］．Int J Cardiol，2013，168(4)：3404-3411．
[18]Eckstein J，Potocki M，Murray K，et al．Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea［J］．Heart(British Cardiac Society)，2012，98(20)：1518-1522．
[19]Cinar O，Cevik E，Acar A，et al．Evaluation of mid-regional pro-atrial natriuretic peptide，procalcitonin，and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients［J］．Am J Emerg Med，2012，30(9)：1915-1920．
[20]Zhou Q，Ye ZJ，Su Y，et al．Diagnostic value of N-terminal pro-brain natriuretic peptide for pleural effusion due to heart failure：a meta-analysis［J］．Heart，2010，96(15)：1207-1211．
[21]Porcel JM，Bielsa S，Morales-Rull JL，et al．Comparison of pleural N-terminal pro-B-type natriuretic peptide，midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure［J］．Respirology，2013，18(3)：540-545．

相似文献/References:

[1]闫福堂,苏宝凤,詹颉,等.血清可溶性ST2与血BNP在心力衰竭患者中的相关性研究[J].现代检验医学杂志,2015,30(06):78.[doi:10.3969/j.issn.1671-7414.2015.06.022]
　YAN Fu-tang,SU Bao-feng,ZHAN Jie,et al.Correlation between Serum Soluble ST2 and BNP in Patients with Heart Failure[J].Journal of Modern Laboratory Medicine,2015,30(05):78.[doi:10.3969/j.issn.1671-7414.2015.06.022]
[2]王 璐,李维娟,杨 靖.血清NT-proBNP和Cys-C水平联合检测在心力衰竭诊断与分型中的应用[J].现代检验医学杂志,2018,33(06):91.[doi:10.3969/j.issn.1671-7414.2018.06.024]
　WANG Lu,LI Wei-juan,YANG Jing.Application of Combined Detection of Serum NT-proBNP and Cys-C Levels in Diagnosis and Typing of Heart Failure[J].Journal of Modern Laboratory Medicine,2018,33(05):91.[doi:10.3969/j.issn.1671-7414.2018.06.024]
[3]屈慧,李娅,黄瑶楠,等.心力衰竭患者外周血RDW 和NT-pro-BNP 联合检测对临床诊断及分级的相关性研究[J].现代检验医学杂志,2020,35(05):65.[doi:10.3969/j.issn.1671-7414.2020.05.017]
　QU Hui,LI Ya,HUANG Yao-nan,et al.Correlation Study on the Combined Detection of RDW and NT-Pro-BNP in Patients with Heart Failure to Clinical Diagnosis and Grading[J].Journal of Modern Laboratory Medicine,2020,35(05):65.[doi:10.3969/j.issn.1671-7414.2020.05.017]
[4]胡小燕,郑　晓,嵇华夏,等.血清 PCT 与 BNP 水平联合检测对慢性阻塞性肺疾病急性加重期并发心力衰竭的临床诊断价值[J].现代检验医学杂志,2021,36(03):128.[doi:10.3969/j.issn.1671-7414.2021.03.029]
　HU Xiao-yan,ZHENG Xiao,JI Hua-xia,et al.Clinical Diagnostic Value of Combined Detection of Serum PCT and BNPLevels in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Complicated with Heart Failure[J].Journal of Modern Laboratory Medicine,2021,36(05):128.[doi:10.3969/j.issn.1671-7414.2021.03.029]
[5]李志强,吴正霞,陈　凯,等.心力衰竭患者并发甲型流感的临床和实验室特征分析[J].现代检验医学杂志,2021,36(03):137.[doi:10.3969/j.issn.1671-7414.2021.03.031]
　LI Zhi-qianga,WU Zheng-xiaa,CHEN Kaia,et al.Analysis on the Clinical and Laboratory Characteristics of Heart FailurePatients with Influenza A[J].Journal of Modern Laboratory Medicine,2021,36(05):137.[doi:10.3969/j.issn.1671-7414.2021.03.031]
[6]杨　英,吴　翔,张文华,等.川芎嗪通过调控组蛋白乙酰化修饰上调SERCA2a对心力衰竭小鼠模型的防治机制研究[J].现代检验医学杂志,2021,36(06):34.[doi:10.3969/j.issn.1671-7414.2021.06.007]
　YANG Ying,WU Xiang,ZHANG Wen-hua,et al.Research on Prevention and Control Mechanism of the Ligustrazine Up Regulates SERCA2a by Regulating Histone Acetylation in A Mouse Model of Heart Failure[J].Journal of Modern Laboratory Medicine,2021,36(05):34.[doi:10.3969/j.issn.1671-7414.2021.06.007]
[7]李丽霞,李 娜.血清MAO 和IL-6 水平诊断慢性肾衰竭并发心力衰竭的价值及与心功能分级的关系[J].现代检验医学杂志,2023,38(01):147.[doi:10.3969/j.issn.1671-7414.2023.01.027]
　LI Li-xia,LI Na.Value of Serum MAO and IL-6 Levels in the Diagnosis of Chronic Renal Failure Complicated with Heart Failure and Their Relationship with Cardiac Function Grading[J].Journal of Modern Laboratory Medicine,2023,38(05):147.[doi:10.3969/j.issn.1671-7414.2023.01.027]
[8]张 囝a,徐钰行b,骆宇琛c,等.重症肺炎脓毒症患者血清Sestrin2，TLR7 水平表达及对心力衰竭的预测价值分析[J].现代检验医学杂志,2024,39(03):131.[doi:10.3969/j.issn.1671-7414.2024.03.022]
　ZHANG Jiana,XU Yuxingb,LUO Yuchenc,et al.Analysis of Serum Sestrin2 and TLR7 Level Expression in Patients with Severe Pneumonic Sepsis and Predictive Value for Heart Failure[J].Journal of Modern Laboratory Medicine,2024,39(05):131.[doi:10.3969/j.issn.1671-7414.2024.03.022]

备注/Memo

备注/Memo:
作者简介：丁春梅(1983-)，女，本科，主管技师，主要从事心血管疾病标志物研究，Tel：0531-51666415，E-mail：dingchunmei2008@qq.com。 通讯作者：胡成进，E-mail：hcj6289@163.com。
更新日期/Last Update: 1900-01-01